ANI Pharmaceuticals | ANIP - Interest Expense On Debt


ANI Pharmaceuticals reported $4.73M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
ANI Pharmaceuticals USD 4.73M 711K Sep/2025
Assertio Holdings USD 758K 1000 Jun/2024
Aurora Cannabis CAD 2.22M 442K Sep/2025
Canopy Growth CAD 8.8M 938K Sep/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Heron Therapeutics USD 500K 900K Sep/2024
Hikma Pharmaceutical USD 20M 2M Jun/2025
Knight Therapeutics CAD 2.37M 6K Sep/2025
Nektar Therapeutics USD 6.02M 420K Sep/2024
Novartis USD 281M 8M Sep/2025
Omeros USD 4.05M 5.16M Sep/2024
Perrigo USD 10.08B 10.04B Sep/2025
Sun Pharmaceuticals INR 998.6M 250.6M Sep/2025
Teva Pharmaceutical Industries USD 220M 17M Dec/2025